BackAtara Biotherapeutics Overview
Atara Biotherapeutics Inc

Atara Biotherapeutics Target Price

Analysts' average 12-month price target for Atara Biotherapeutics is $13.

Get informed when a big investor buys or sells

+ Follow

Share Price

$8.91

Average Target Price

$13.0045.9% upside

1 analysts in the last 4 months

High: $13 | Low: $13

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-08Canaccord Genuity$1345.9% upsideOpen
2026-01-13New Street$632.7% downsideOpen
2025-12-19Canaccord Genuity$25180.6% upsideOpen
2024-11-13Stifel NicolausBenjamin Burnett$1012.2% upsideOpen
2024-08-16Mizuho SecuritiesSalim Syed$18102% upsideOpen
2022-08-09Goldman Sachs$366.3% downsideOpen
2022-05-24Goldman Sachs$455.1% downsideOpen

Atara Biotherapeutics (ATRA) FAQ

Atara Biotherapeutics posts a target price of $13. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $13 for ATRA means covering analysts, on average, see the stock 45.9% upside of $8.91 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ATRA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Atara Biotherapeutics's other metric pages and overview cover the third.

Judging Atara Biotherapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $13 here, then scan peer and history charts to see if the gap is persistent.